Orphan Drug Companies Warned To Beware Of The Dutch Lock System
Companies selling orphan medicines in the Netherlands need to prepare for the likelihood that their products will enter the so-called lock system, which means they will come under extra scrutiny and take longer to reach patients.
You may also be interested in...
IMC, the R&D-based pharmaceutical industry association in Canada, says the guideline will “exacerbate an already unpredictable regulatory environment.”
Canada’s health technology appraisal body is seeking feedback on guidance on the use of real-world evidence in decision making.
ANVISA, Brazil’s medicines regulator, is asking for feedback on the regulatory pathway for biosimilars.